Another DPP-4 inhibitor, sitagliptin, has been shown to decrease LV cardiomyocyte Fpassive and enhance global LV performance due to elevated cGMP levels, PKG activity, and improved titin phosphorylation in a mouse model of obesity and DM [79]. The gene discussed is PRKG1; the disease is obesity disorder.